Companies: 10,795·Total market cap: $144.5T
LivaNova PLC

LivaNova PLC

LIVNNASDAQHealthcare● Active
$74.46
+$2.10(+2.90%)
Market Cap$4.1B
P/E Ratio
52W High$75.815
52W Low$41.015

LivaNova PLC (LIVN) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

livn · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for LivaNova PLC (LIVN) measures how much investors pay for each dollar of the company's trailing earnings. LIVN's current PE ratio of 38.05x is calculated by dividing its stock price of $74.46 by its TTM earnings per share of $1.96. −37.0% discount vs 5Y avg 60.4x

38.05x
P/E Ratio (TTM)37.0%

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
16.08x
FY2027 est. EPS $4.63
Based on 6 analysts
EPS (TTM)
$1.96
TTM · diluted EPS
PEG Ratio
0.32
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · LivaNova PLC SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2006 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 60.4x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

Historical PE Range

Past 9 fiscal years · Front-end computed
Average
54.7x
9-yr mean
Median
41.6x
9-yr midpoint
Minimum
24.7x
Lowest year
Maximum
158.9x
Highest year
38.1x ← Now
24.7x
Min
Q1 · 25%41.6x
Median
Q3 · 75%158.9x
Max
Within Historical Range

At 38.05x, LIVN's current P/E is within its average historical range over the past 9 fiscal years.

33th percentileHigher than 3 of 9 historical fiscal year readings

Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.

PE Ratio vs Peers

Medical - Devices · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
LivaNova PLC
LivaNova PLCYou
LIVN
$4.1B38.05x$1.96
Alphatec Holdings, Inc.
Alphatec Holdings, Inc.
ATEC
$1.2BN/A-$0.96
Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc.
CDTX
$5.6BN/A-$26.75
Heartflow, Inc. Common Stock
Heartflow, Inc. Common Stock
HTFL
$2.5BN/A-$0.32
IDEAYA Biosciences, Inc.
IDEAYA Biosciences, Inc.
IDYA
$2.7BN/A-$1.28
Disc Medicine, Inc.
Disc Medicine, Inc.
IRON
$2.5BN/A-$6.01
Legend Biotech Corporation
Legend Biotech Corporation
LEGN
$5.7BN/A-$1.61

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-4.45
2024-12-31
FY2024
39.72x$1.17-75.0%
2023-12-31
FY2023
158.94x$0.33
2022-12-31
FY2022
$-1.61
2021-12-31
FY2021
$-2.68
2020-12-31
FY2020
$-7.18
2019-12-31
FY2019
$-3.26
2018-12-31
FY2018
$-3.91
2017-12-31
FY2017
$-0.52
2016-12-31
FY2016
$-1.29

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for LivaNova PLC (LIVN) measures how much investors pay for each dollar of the company's trailing earnings. LIVN's current PE ratio of 38.05x is calculated by dividing its stock price of $74.46 by its TTM earnings per share of $1.96.

PE Ratio = Stock Price ÷ EPS (TTM)
= $74.46 ÷ $1.96 = 38.05x
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

LIVN pe ratio · 6 questions

LIVN's current PE ratio is 38.05x as of 2026-06-08, based on a stock price of $74.46 and TTM EPS of $1.96. Data sourced from Financial Modeling Prep via LIVN's SEC 10-K and 10-Q filings.

LIVN PE ratioWhat is LIVN PE ratioCurrent PE ratio of LIVNLIVN PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · LivaNova PLC SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08